FDA and EMA accept review of JAK3/TEC inhibitor ritlecitinib
ADC评论
September 21, 2022
On September 19, 2022, Pfizer announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the oral JAK3/TEC
